Currently, dimethyl fumarate (DMF) targets the Nrf2 pathway and was approved by the FDA in 2013 for the clinical treatment of multiple sclerosis (MS), which is another autoimmune disease. This evidence concerns the gene NFE2L2 and multiple sclerosis.